HEP-C PILOT

这个子项目是许多研究子项目中的一个 由NIH/NCRR资助的中心赠款提供的资源。子项目和 研究者（PI）可能从另一个NIH来源获得了主要资金， 因此可以在其他CRISP条目中表示。所列机构为 研究中心，而研究中心不一定是研究者所在的机构。 流行病学和生物学证据支持慢性丙型肝炎感染与2型糖尿病之间存在关联。然而，丙型肝炎病毒（HCV）的清除是否与葡萄糖代谢的改善有关尚不清楚。为了解决这个问题，我们提出了一个为期2年的前瞻性研究的个人开始治疗慢性肝炎。C感染。该项目的具体目标是： C治疗对糖耐量、胰岛素抵抗和胰岛素分泌的影响。 参与者将在开始丙型肝炎治疗前1周和治疗期间每3个月接受一次研究访视。每次访视将包括标准化访谈、人体测量和2小时口服葡萄糖 胰岛素水平的耐受性测试。在获得书面知情同意后，将从病历中获取其他临床数据。

This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. Epidemiologic and biologic evidence support an association between chronic hepatitis C infection and type 2 diabetes mellitus. However whether clearance of hepatitis C virus (HCV) is associated with improved glucose metabolism is not known. To address this issue, we propose a 2-year prospective study of individuals initiating therapy for chronic hepatitis. C infection. The specific aim of the project is: To determine the effects of hepatitis C treatment on glucose tolerance, insulin resistance, and insulin secretion. Participants will undergo research visits 1 week prior to initiating hepatitis C therapy and every 3 months during therapy. Each visit will consist of a standardized interview, 'anthropometry, and a 2-hour oral glucose tolerance test with insulin levels. Additional clinical data will be obtained, following written informed consent, from medical records.